3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2-a]-pyridine as Positive Allosteric Modulators of GABAA Receptor with Potential Antipsychotic Activity

2017 ◽  
Vol 8 (6) ◽  
pp. 1291-1298 ◽  
Author(s):  
Monika Marcinkowska ◽  
Marcin Kołaczkowski ◽  
Krzysztof Kamiński ◽  
Adam Bucki ◽  
Maciej Pawłowski ◽  
...  
2006 ◽  
Vol 59 (7) ◽  
pp. 445 ◽  
Author(s):  
David I. B. Kerr ◽  
Jennifer Ong ◽  
Michael V. Perkins ◽  
Rolf H. Prager ◽  
Ni Made Puspawati

A series of 15 analogues of fendiline, and 34 derivatives of N-(3-phenylpropyl)-1-arylethylamine have been prepared for evaluation as positive allosteric modulators of GABAB receptors. The most active (EC50, 10 nM) was N-(3,3-diphenylpropyl)-1-(3-chloro-4-methoxyphenyl)ethylamine 6g.


2018 ◽  
Vol 19 (10) ◽  
pp. 3105 ◽  
Author(s):  
Magda Kondej ◽  
Piotr Stępnicki ◽  
Agnieszka A. Kaczor

Polypharmacology is nowadays considered an increasingly crucial aspect in discovering new drugs as a number of original single-target drugs have been performing far behind expectations during the last ten years. In this scenario, multi-target drugs are a promising approach against polygenic diseases with complex pathomechanisms such as schizophrenia. Indeed, second generation or atypical antipsychotics target a number of aminergic G protein-coupled receptors (GPCRs) simultaneously. Novel strategies in drug design and discovery against schizophrenia focus on targets beyond the dopaminergic hypothesis of the disease and even beyond the monoamine GPCRs. In particular these approaches concern proteins involved in glutamatergic and cholinergic neurotransmission, challenging the concept of antipsychotic activity without dopamine D2 receptor involvement. Potentially interesting compounds include ligands interacting with glycine modulatory binding pocket on N-methyl-d-aspartate (NMDA) receptors, positive allosteric modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, positive allosteric modulators of metabotropic glutamatergic receptors, agonists and positive allosteric modulators of α7 nicotinic receptors, as well as muscarinic receptor agonists. In this review we discuss classical and novel drug targets for schizophrenia, cover benefits and limitations of current strategies to design multi-target drugs and show examples of multi-target ligands as antipsychotics, including marketed drugs, substances in clinical trials, and other investigational compounds.


2017 ◽  
Vol 234 (14) ◽  
pp. 2091-2101 ◽  
Author(s):  
Kathryn L. Schwienteck ◽  
Guanguan Li ◽  
Michael M. Poe ◽  
James M. Cook ◽  
Matthew L. Banks ◽  
...  

2012 ◽  
Vol 23 (8) ◽  
pp. 790-801 ◽  
Author(s):  
Martine Hofmann ◽  
Krisztina Sz. Kordás ◽  
Andreas Gravius ◽  
Kata Bölcskei ◽  
Chris G. Parsons ◽  
...  

2020 ◽  
Vol 11 (11) ◽  
pp. 2204-2211
Author(s):  
Annet E. M. Blom ◽  
Justin Y. Su ◽  
Lindsay M. Repka ◽  
Sarah E. Reisman ◽  
Dennis A. Dougherty

Sign in / Sign up

Export Citation Format

Share Document